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Synaptopathies are diseases with synapse defects as shared pathogenic features, encompassing neurodegenerative disorders such
as Parkinson’s disease (PD). In sporadic PD, the most common age-related neurodegenerative movement disorder, nigrostriatal
dopaminergic deficits are responsible for the onset of motor symptoms that have been related to 𝛼-synuclein deposition at
synaptic sites. Indeed, 𝛼-synuclein accumulation can impair synaptic dopamine release and induces the death of nigrostriatal
neurons. While in physiological conditions the protein can interact with and modulate synaptic vesicle proteins and membranes,
numerous experimental evidences have confirmed that its pathological aggregation can compromise correct neuronal functioning.
In addition, recent findings indicate that 𝛼-synuclein pathology spreads into the brain and can affect the peripheral autonomic and
somatic nervous system. Indeed, monomeric, oligomeric, and fibrillary 𝛼-synuclein can move from cell to cell and can trigger the
aggregation of the endogenous protein in recipient neurons. This novel “prion-like” behavior could further contribute to synaptic
failure in PD and other synucleinopathies. This review describes the major findings supporting the occurrence of 𝛼-synuclein
pathology propagation in PD and discusses how this phenomenon could induce or contribute to synaptic injury and degeneration.
1. Introduction
Pathological accumulation of 𝛼-synuclein in the brain is
a typical neuropathological hallmark of Parkinson’s disease
(PD), a complex neurodegenerative disorder characterized
by motor disability that derives from the neurodegenera-
tion of nigrostriatal dopaminergic neurons. The presence of
Lewy bodies (LB) and Lewy neurites (LN), proteinaceous
inclusions whose main constituent is fibrillary-aggregated 𝛼-
synuclein, is a defining neuropathological alteration observed
in the brain of affected patients. In the last few years, it has
become evident that PDmay be considered as a synaptopathy
[1, 2]. Indeed, striatal dopaminergic terminal loss appears
to precede neurodegeneration in the substantia nigra [3, 4]
and the deposition of 𝛼-synuclein, which is considered as a
causative factor for the onset of the disorder, mainly affects
synaptic terminals in its early stages [5, 6]. Nonetheless, the
exact molecular mechanisms that determine the selective
vulnerability of nigrostriatal synapses to 𝛼-synuclein depo-
sition are still enigmatic. One of the reasons for the reduced
resilience of dopaminergic terminals to 𝛼-synuclein accumu-
lation may be the fact that dopamine neurons of the sub-
stantia nigra show relatively large axonal lengths with 10–100
times the number of synapses of neighboring neuronal cells
[7]. This implies that these cells require an elevated energy
demand to efficiently sustain the trafficking of organelles
and vesicles to allow proper synapse functioning [8]. Hence,
they might result particularly susceptible even to subtle
homeostatic changes at synaptic sites, which constitute their
major source of energy consumption.
Compelling evidence indicates that 𝛼-synuclein can
spread fromdiseased to healthy cells, thus contributing to dis-
ease worsening [9]. Indeed, graft-derived dopamine neurons
can develop LB pathology several years after transplantation
[10–12], an event that can be responsible for the loss of
beneficial effects of cell therapy along with time. In addition,
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both neurons and astrocytes have been found to internalize
disease-associated 𝛼-synuclein in the postmortem brain of
subjects with Lewy pathology, suggesting prion-like spread
of 𝛼-synuclein by uptake from surrounding structures [13].
It is worth noting that the progression of PD symptoms
seems to correlate with the topographical brain propagation
of 𝛼-synuclein pathology between anatomically intercon-
nected brain areas [14, 15], suggesting the occurrence of trans-
synaptic spreading of pathology. This is not surprising when
considering that 𝛼-synuclein is a synaptic-vesicle associated
protein [16]. Studies on experimental models of PD have
confirmed the occurrence of trans-synaptic transmission of
pathological 𝛼-synuclein in vivo [17–20]. In light of evidences
supporting host-to-graft 𝛼-synuclein passage, as well as the
ability of the protein to propagate protein misfolding in
recipient cells, a “prion-like” hypothesis of PD has been pos-
tulated [21–29]. Indeed, prions are transmissible misfolded
conformers of the prion protein, PrP, which seed further
generation of infectious proteins [30]. However, the mecha-
nismsmediating 𝛼-synuclein release, uptake, and behavior in
recipient cells deserve further investigation to definitely assert
that 𝛼-synuclein behaves like a prion. For instance, not all
the postmortem analyses on PD cases seem to confirm the
caudo/rostral spread of 𝛼-synuclein pathology throughout
the brain described by Braak [14, 15]. Moreover, the ability
to seed aggregation in recipient cells has been found to be
dependent on high concentration of aggregates in the face of
the need of low amount of aggregates to induce cytotoxicity
[31]. These evidences pose into question both the trans-
synaptic spreading hypothesis and the prion-like behav-
ior of 𝛼-synuclein. Nonetheless, cell-to-cell transmission
of 𝛼-synuclein can occur with Ca2+-dependent exosome-
mediated release [32] or nonclassical exocytosis [33] as
the most plausible candidate mechanisms for 𝛼-synuclein
ejection. Finally, what could be the transmissible form of
the protein that can mediate toxicity and/or function as
seed for “misfolding” propagation in recipient cells between
monomeric, oligomeric, and fibrillary 𝛼-synuclein still needs
to be clarified. In this review, we describe the features of 𝛼-
synuclein pathology spreading in PD and discuss how this
could contribute to synaptic damage.
2. Alpha-Synuclein Function at
the Dopamine Synapse
Αlpha-synuclein was first identified in the synaptic vesicles
and nuclei of the electric organ of Torpedo Californica [34].
The protein is highly expressed in presynaptic terminals of
the brain and peripheral nervous system, where it associates
with the synaptic vesicle apparatus [35–37]. The expression
of 𝛼-synuclein is elevated within the synapses of nigral
dopamine neurons [38]. There, the protein can modu-
late synaptic dopamine release by directly modulating the
dopamine transporter (DAT), synapsin III, the small GTP-
binding protein Rab3A, and the soluble N-ethylmaleimide
sensitive fusion attachment protein receptor (SNARE) pro-
teinmember vesicle associatedmembrane protein-2 (VAMP-
2) [6]. Indeed, it catalyzes the entry of VAMP-2 into the
SNARE complex [39] and enhances DAT localization at the
plasma membrane [40], which consistently is impaired by
𝛼-synuclein aggregation [41, 42]. The toxicity exerted by 𝛼-
synuclein deposition in dopaminergic neurons is rescued by
Rab3A expression, suggesting that this protein is relevant for
its normal function [43]. Conversely, 𝛼-synuclein membrane
association is regulated by the Rab3A recycling machinery
and presynaptic activity [44]. Finally, synapsin III distribu-
tion and expression in dopaminergic neurons is regulated
by 𝛼-synuclein, while synapsin III gene silencing inhibits 𝛼-
synuclein aggregation [4].
In the synapse, likewise in the other neuronal compart-
ments,𝛼-synuclein exists in a dynamic equilibriumbetween a
soluble state and amembrane-bound state, with its affinity for
synaptic vesicles being higher than that for cell membranes
[45–47] (Figure 1(a)). However, when interacting with cell
membranes, the protein presents higher affinity for lipid
rafts [48]. The interaction between 𝛼-synuclein and lipid
membranes is also relevant for the protein to exert its
functions [49]. This, notwithstanding, 𝛼-synuclein presents
elevated structural plasticity and its effective conformation
in soluble and membrane-bound state is matter of debate.
While some evidences support the existence of a stable
cytosolic tetrameric form of the protein, other studies have
shown that it can be found as a disordered monomer in the
central nervous system (CNS) and other mammalian cells
or that these forms both coexist in a dynamic equilibrium
[50, 51]. More recently, the existence of a stable dimer has
been suggested by computational evidences [52]. As for the
aminoacidic sites involved in the interaction with mem-
branes, numerous studies have reported a key role for the
ones located at the N-terminal portion of 𝛼-synuclein [53].
Jiang and coauthors [54], by coupling neutron reflectometry
(NR) and fluorescence spectroscopy analysis, have found
that the N- and C-terminal regions near positions 4 and
94 are anchored to the membrane, while the putative linker
spanning residue 39 samples multiple conformations, which
are sensitive to the chemical nature of the membrane surface.
The mechanism of 𝛼-synuclein binding to lipid membranes
has been found to be primarily dependent on the surface
charge density of the lipid bilayer and the phase state of the
lipids, with 𝛼-synuclein possessing lipid ordering effect and
thermally stabilizing vesicles [55].These findings suggest that
this process might be tunable by environmental changes.
Collectively, these evidences support that subtle changes
in 𝛼-synuclein structural folding, likewise the formation of
oligomers or insoluble aggregates, can severely compromise
the activity of dopaminergic neurons, with the adjunct of cell-
to-cell transmission likely worsening and perpetrating the
related injury.
3. Central and Peripheral Localization of
Neuronal 𝛼-Synuclein Pathology in PD:
Trans-Synaptic or Systemic Spreading?
The presence of different forms of 𝛼-synuclein in cere-
brospinal fluid (CSF), blood plasma [56–58], and saliva
[59] coupled to the discovery of 𝛼-synuclein pathology in
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Figure 1:Monomeric, oligomeric, andfibrillary𝛼-synuclein at the synaptic terminal. (a)Monomeric𝛼-synucleinmodulates synaptic function
by controlling synaptic vesicle release. This form of the protein can be released in association with exosomes, activates microglial cells,
and can be internalized at postsynaptic sites. (b) Oligomeric 𝛼-synuclein formation is enhanced by interaction of monomeric protein
with DA. Alpha-synuclein oligomers can form a stable adduct with the toxic dopamine metabolite DOPAL. Oligomers can be released
in association with extracellular vesicles and then activate microglia. Alpha-synuclein oligomers can disrupt synaptic vesicles membranes
as well as presynaptic and postsynaptic membranes. Exogenous 𝛼-synuclein oligomers can damage lipid rafts and affect LTP by activating
NMDA receptors. Intracellular 𝛼-synuclein oligomers with endogenous or exogenous origin impair mitochondrial functions and cytoskeletal
architecture. (c) Fibrillary-aggregated 𝛼-synuclein alters synaptic vesicle release by clustering synaptic vesicles and by perforating plasma
membrane. Extracellular fibrils deriving from degenerating neurons in the PD brain can activate microglial cells and actively contribute
to alpha-synuclein pathology spreading. The formation of endogenous 𝛼-synuclein fibrils can reduce seeding activity and toxicity although
exogenous 𝛼-synuclein fibrils function as a seed for the aggregation of endogenous 𝛼-synuclein in recipient cells.
embryonic nigral transplants of PD patients [10, 11, 60]
suggested that 𝛼-synuclein canmove from cell to cell and can
initiate pathology in recipient neurons. It is well established
that 𝛼-synuclein can be secreted [61, 62], a process that is
thought to be mainly mediated by exosomal vesicles [63, 64].
Compelling evidence indicates that in PD 𝛼-synuclein
pathology is not confinedwithin the brain. LB-like aggregates
of the protein have been found in the dorsal root ganglia, as
well as in several tracts of the peripheral nervous system such
as gastrointestinal innervation, motor nerves innervating the
pharyngeal muscles, cranial and spinal nerves, skin nerves,
and olfactory epithelium [8, 65–70]. The presence of these
peripheral aggregates has been proposed to associate with
typical PD premotor symptoms [71] and could contribute
to disease onset in the brain, as supported by evidences
indicating that vagotomy diminishes the risk to develop the
disorder [20]. As hypothesized by Braak and colleagues [14],
caudo-rostral spreading of 𝛼-synuclein has been found to
occur through vagal connections in experimental models
of PD [17]. Resection of the vagal autonomic projection
impedes the peripheral-to-CNS diffusion of pathological 𝛼-
synuclein and the onset of PD-like motor phenotype in
the chronic intragastric rotenone model of PD [19], sup-
porting a causative role for protein spreading in the onset
of the disorder. Vagotomy eliminates most, but not all, 𝛼-
synuclein-positive neurites in the plexus, thus providing a
candidate pathway for the retrograde transport of putative
PD pathogens or toxins from the enteric nervous system
to the central nervous system [67]. However, even vagal
nerve impairment per se has been found to induce dopamine
functional damage, therefore suggesting that the vagal degen-
eration occurring in the PD brain [72, 73] might be pivotally
involved in PDpathogenesis independently from𝛼-synuclein
pathological spreading. Studies in rodents have shown that
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vagal afferent endings in the myenteric plexus and the
gastrointestinal smooth muscle do not express 𝛼-synuclein,
whereas virtually all vagal preganglionic projections to the
gut show 𝛼-synuclein immunopositivity both in axons and in
terminal varicosities in apposition with myenteric neurons.
However, some other studies raise some concerns about
its validity as 𝛼-synuclein accumulation within the periph-
eral nervous system can occur also in neurologically intact
subjects with aging [74]. Not by chance, PD and aging have
been proposed to be a unique entity and the disease has
been postulated tomanifest in all subjects whether they could
live long enough [75]. In addition, typical manifestations
of aging such as frailty that interestingly has been found
to associate with brain neuropathological accumulation of
LB and nigral neuronal loss [76, 77] also characterize PD
[78]. Other studies, failing to detect either the typical pattern
of topographical distribution of 𝛼-synuclein pathology in
the postmortem brain of affected patients [79, 80] or the
development of pathology spreading following preformed
fibril-inoculation in vivo, cast further confusion over the
prion-like hypothesis.
Recent studies indicate that 𝛼-synuclein oligomers are
increased in red blood cells and CSF of PD subjects and
could serve as biomarkers of disease [81, 82]. The levels of 𝛼-
synuclein are also increased in peripheral lymphocytes [83] as
well as in plasma andCNS-derived exosomes of affected indi-
viduals [84].The systemic spreading of the protein could thus
also involve exosomal-mediated release and biological fluids.
Indeed exosomes are small membrane vesicles which result
from exocytosis of multivesicular bodies. They function as
mediators of intercellular communication, as they transfer
specific proteins, lipids, microRNAs, and DNA between cells.
Because of their small size, exosomes can move from the
site of discharge by diffusion and reach several biological
fluids, such as blood, CSF, urine, and synovial fluid [85].
Consistently, plasma exosomal 𝛼-synuclein is likely CNS-
derived and increased in PD [84] and CSF exosomes have
been found to induce 𝛼-synuclein aggregate formation in
recipient healthy cells [86]. This suggests that the circulatory
system could also mediate 𝛼-synuclein systemic spreading,
with the choroid plexus being likely involved in the passage
of alpha-synuclein from the blood to the brain and vice versa.
Notably, the presence of increased 𝛼-synuclein immunoreac-
tivity at this site has been described in PD [13]. However, it
still remains to be determinedwhether a link effectively exists
between peripheral and brain 𝛼-synuclein deposition. In the
case that they might constitute a unique phenomenological
entity, defining what might come first between central and
peripheral deposition could be crucial for determining the
causes of PD.
4. Toxicity of 𝛼-Synuclein Oligomers and
Fibrils: A Still Unresolved Dichotomy
Aggregation of 𝛼-synuclein is a critical step in the etiology
of PD, with prefibrillar oligomers of the protein that might
constitute the direct precursors of fibrils being involved in
neurodegenerative process [87, 88]. Even if the injection of
fibrils into the rat brain is found to be more toxic than that of
oligomers and ribbons, as it induces neurodegeneration and
motor impairment, all these species can self-amplify in vivo
and lead to PD/multiple system atrophy-like alterations in the
injected animals [89].This suggests that strain-specific prion-
like infectivity and symptomatology characterize different
𝛼-synuclein conformers, whose biochemical nature is still
unknown. Therefore, asserting which, between fibrils or
oligomers, are the most toxic species is still difficult at
present. Nonetheless, the analysis of both oligomers’ and
fibrils’ structure could help to elucidate this conundrum.
In addition, data supporting that monomeric, oligomeric,
and fibrillary 𝛼-synuclein can activate microglial cells [90–
93] suggest that all these forms of the protein could affect
neuronal homeostasis by modulating microglia function that
could be either protective or detrimental in PD [94].
As for oligomers, those formed by a peptide derived from
residues 36–55 of 𝛼-synuclein were recently characterized
by X-ray crystallography [95]. The authors showed that this
specific peptide is able to adopt a 𝛽-hairpin structure, which
assembles in a hierarchical fashion. Three 𝛽-hairpins then
assemble to form a triangular trimer and three copies of
the triangular trimer then assemble to form a basket-shaped
nonamer that couple to form an octadecamer. Following
molecular modeling analysis, these authors also proposed
that full-length 𝛼-synuclein might be able to assemble in
this fashion. Circular dichroism spectroscopy demonstrated
that the peptide 36–55 interacts with anionic lipid bilayer
membranes, like oligomers of full-length 𝛼-synuclein, and is
found to be toxic in neuronal cell models. Other cryoelectron
microscopy studies have shown that oligomers isolated dur-
ing fibril formation possess a hollow cylindrical architecture
with similarities to certain types of amyloid fibril [96].
The formation of 𝛼-synuclein dimers has been described
to initiate aggregation and neurotoxicity [97]. Computer
modeling and cell-based studies have revealed that upon
interaction with plasma membranes 𝛼-synuclein rapidly
penetrates them, changing its conformation from 𝛼-helical
toward a coiled structure. This penetration facilitates the
incorporation of additional 𝛼-synuclein monomers to the
complex and subsequent displacement of phospholipids and
formation of oligomers in the membrane [98]. Consistently,
𝛼-synuclein oligomers neurotoxicity in vivo has been found
to be mediated by membrane disruption [99].
Chen and coauthors described that stable toxic 𝛼-
synuclein oligomeric species with a hollow cylindrical archi-
tecture with similarities to certain types of amyloid fibril can
be trapped during fibril formation [96]. Their study showed
that the 𝛽-sheet geometry acquired in the early stages of
the self-assembly process plays a key role in dictating the
kinetic stability and the pathological nature of individual
oligomeric species. Spectroscopy studies have also shown
that whereas fibrils adopt a parallel arrangement oligomers
adopt an antiparallel 𝛽-sheet structure [100], thus suggest-
ing that differences in the toxicity of these species might
rely on their diverse conformations. The neurotoxicity of
oligomers has been demonstrated in different experimental
conditions. Alpha-synuclein overexpression in neuroblas-
toma cells causes the formation of 𝛼-synuclein oligomeric
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species, whose presence is associated with mitochondrial
fragmentation and autophagic-lysosomal pathway activation
in live cells [101].The accumulation of oligomeric and fibrillar
forms of 𝛼-synuclein has a negative impact on mitochondria
function by inhibiting mitochondria complexes IV and V in
the striatum [102], reducing mitochondrial Ca2+ release and
NADH oxidation [103]. Permeabilization of mitochondria
membranes can also be induced by 𝛼-synuclein oligomers
[104–107]. The accumulation of toxic 𝛼-synuclein oligomers
in the endoplasmic reticulum (ER) has been described as
a feature of 𝛼-synucleinopathies [108, 109]. Recently, 𝛼-
synuclein oligomers have been found to interact with metal
ions to induce oxidative stress and neuronal death in PD [110].
Interestingly, the oligomer-induced reactive oxygen species
(ROS) production was independent of several known cellular
enzymatic sources and relied solely on the presence of free
metal ions.
Studies on human 𝛼-synuclein transgenic mice have
shown that the accumulation of oligomers mainly occurs at
synaptic sites and is crucial for the induction of synaptic and
neuronal degeneration [111]. Consistently, the formation of 𝛼-
synuclein soluble oligomers can reduce neuronal excitability
of neocortical pyramidal cells, suggesting that it could impact
on network activity [112]. Oligomers have been found to affect
synaptic function by changing lipid raft composition and
increasing N-methyl-D-aspartate (NMDA) receptor activa-
tion at postsynaptic membranes [113, 114].
Alpha-synuclein oligomers could thus easily impinge
on synaptic resilience by disrupting membranes, inducing
mitochondrial depolarization, altering cytoskeleton dynam-
ics, impairing protein clearance pathways, and enhancing
oxidative stress [115] (Figure 1(b)). In addition, the preferen-
tial degeneration of dopaminergic neurons in PD [116, 117]
led to the hypothesis that dopamine may play an impor-
tant role in 𝛼-synuclein oligomerization [118]. The oxide
forms of dopamine, generated by oxidative stress, acceler-
ate formation of 𝛼-synuclein oligomers as an endogenous
protofibril stabilizer, demonstrating the connection between
dopamine and𝛼-synuclein oligomer formation [119, 120].The
toxic dopamine metabolite 3,4-dihydroxyphenylacetalde-
hyde (DOPAL) can compromise the membrane-binding
affinity of 𝛼-synuclein to synaptic vesicles, as well as its
fibrillation, by forming an adduct with the protein, thus
reducing its functional ability to modulate synaptic vesicles
[121].
Fibrils exert their toxic actions by activating other detri-
mental processes in neuronal cells. This may be related to the
different conformation of oligomers and fibrils. Consistently,
Curtain and coauthors [122], by using small angle X-ray
scattering and ensemble optimizationmodeling studies, were
able to demonstrate that 𝛼-synuclein oligomers and fibrils
originate in two distinct conformer pools, with E53T and
E45Kmutations enhancing the tendency to formfibrils, while
the A30P conferring propensity toward oligomer assembly.
This is in line with previous data reporting that A30P mutant
𝛼-synuclein forms different fibril structures [123] and that
mutations in the KTKE(Q)GV imperfect amino acid repeats
in the N-terminal part of the protein can also affect its
tendency toward fibril formation [124]. Mutant 𝛼-synuclein
preferentially shifts frommonomer to fibrils, thus suggesting
that the formation of these species plays a crucial role in
the pathophysiology of early-onset PD [125, 126]. Whether
the lipid bound 𝛼-helical form or the unfolded state initiates
protein aggregation remains to be determined.
X-ray and electron diffraction of the 𝛼-synuclein aggre-
gates showed that the fibrils consist of a 𝛽-sheet structure
in which the 𝛽-strands run perpendicularly to the long fiber
axis [127]. A flexible break close to residues 52–55 has been
found to be relevant for fibril formation [128], while the
negative charges and aromatic residues at the C-terminal
region play a modulatory role on fibrillation [129, 130]. In
addition, molecular dynamics simulations allowed observing
that residues 36−55 of the nonamyloid component (NAC)
domain, in the central region of the protein, are important
for the formation of 𝛽-hairpin and that the point mutations
stabilize this 𝛽-hairpin that represented the first step of 𝛼-
synuclein aggregation [95].
Αlpha-synuclein fibrils can exert toxicity by disrupting
the normal distribution of membrane proteins and synap-
tic vesicles [6], perforating plasma membranes [131, 132],
triggering cellular responses [133], and causing death in cell
systems [134] (Figure 1(c)). However, the stabilization of
fibril clusters can prevent fragmentation and reduces seeding
activity and toxicity [135]. In addition, 𝛼-synuclein structure
is strictly dependent onmembrane interactions that can both
accelerate [136, 137] and inhibit [136, 138, 139] fibril formation.
5. Mechanisms of 𝛼-Synuclein Release
Since 2003, Braak and colleagues had speculated that, in
idiopathic PD, LB pathology could spread from the enteric
nervous system or the olfactory bulb to precise brain regions
during the progression of the disease [14], thus suggesting
the occurrence of cell-to-cell 𝛼-synuclein transmission. The
existence of this phenomenon was confirmed thanks to post-
mortem studies carried out on the brain of PD patients who
had received transplants of mesencephalic neurons 14 years
prior to the demise. Indeed, the analysis of autopsy samples
showed that grafted neurons had developed LB pathology
[10, 60]. Host-to-graft transmission was then corroborated in
different experimental models in vivo [140–142].
The first evidence in favor of 𝛼-synuclein release was
provided by Dixon and colleagues that demonstrated that,
in yeasts, the protein can be delivered to the extracellular
space through the classical ER-to-Golgi secretory pathway
[143]. However, these findings were not confirmed in SH-
SY5Y cells, where 𝛼-synuclein has been observed to be
mediated by ER/Golgi-independent unconventional exocy-
tosis pathway [33, 62] and in a Ca2+-dependent manner
by exosomes [63], respectively. Protein overexpression, mis-
folding, and posttranslational modifications can promote
𝛼-synuclein accumulation and release, caused by impaired
intracellular degradation. Several cellular mechanisms have
been found to mediate 𝛼-synuclein degradation, includ-
ing the ubiquitin-proteasome system (UPS) and lysosome-
mediated digestion [144]. In PD, dysfunction of the UPS
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causes the accumulation of misfolded 𝛼-synuclein and is
thought to be highly implicated in the pathogenesis of PD
[145–149]. However, ubiquitination of 𝛼-synuclein in LB has
been found to constitute a pathological event not associated
with impairment of proteasomal function [150]. Alpha-
synuclein can also be cleared by the autophagy-lysosome
pathway (ALP). Indeed, Cuervo [151] showed that wild type
𝛼-synuclein is translocated into lysosome for degradation.
Conversely, aggregated 𝛼-synuclein can cause a malfunction
in lysosomal degradation pathway [152]. Remarkably, also
aging may represent another important factor related to the
dysfunction of protein control systems [145, 151, 153–155]
causing a vicious circle that exacerbate the accumulation of
toxic forms of 𝛼-synuclein.
The oxidized forms of 𝛼-synuclein are preferentially
secreted [62] and studies in induced pluripotent stem cell-
derived neurons harboring 𝛼-synuclein gene locus triplica-
tions showed that increased intracellular levels of the protein
foster its release [156]. However, the amount of released 𝛼-
synuclein deriving from injured neurons is likely very low as
neuronal damage and neurodegeneration do not exacerbate
its propagation [18].
At the subcellular level, it has been observed that, in
neurons, 𝛼-synuclein can be found in the three endosomal
compartments and translocate across them (early, late, and
recycling endosomes) [32].This pathway could be involved in
the process of protein release [32]. Moreover, treatments that
could disturb the homeostasis of the endosomal system alter
𝛼-synuclein spreading [63, 157]. From the early endosomes,
a portion of the protein can be translocated to the recycling
endosomal compartment, which can fuse with the plasma
membrane to allow the release of soluble forms of 𝛼-
synuclein. This process seems to be mediated by the interac-
tion between 𝛼-synuclein and Rab GTPases [158]. The por-
tion of protein that remains in the endosomal compartment is
targeted to multivesicular bodies (MVBs), which usually fuse
with lysosomes for protein degradation. In diseased neurons,
where the accumulation of toxic𝛼-synuclein aggregates could
perturb the activity of protein clearance mechanisms, MBVs
can release the intraluminal vesicles in the extracellular space
as exosomes [159]. Remarkably, numerous findings [63, 157,
160, 161] support that 𝛼-synuclein can be released in associ-
ation with exosomes, small vesicles (40–100 nm in diameter)
originating from the endosomal compartment. Exosomes can
be secreted and interact with cell membranes in a cell type-
dependent manner and recipient cells can internalize them
through different endocytic mechanisms [162]. In several
neurodegenerative diseases, exosomes seem to play the role of
“garbage” carrier, acting as an alternative pathway of protein
eliminationwhen intracellularmechanisms are engulfed [163,
164]. The process through which 𝛼-synuclein is targeted to
the endosomal compartment is still matter of study, with
a recent work suggesting posttranslational modifications of
the protein being involved. In particular, the conjugation
of Small Ubiquitin like Modifier (SUMO) also defined as
SUMOylation of 𝛼-synuclein triggers its internalization in
exosomes [160]. To date, SUMOylation serves to regulate the
solubility of aggregation-prone proteins [165, 166], as well as a
ubiquitin-independent endosomal sorting complex required
for transport (ESCRT) sorting signal, regulating the extra-
cellular vesicle release of 𝛼-synuclein [160]. Interestingly,
ubiquitinated forms of 𝛼-synuclein have been found to be
present in LB [167, 168] and the ubiquitination of the protein
has been found to increase its aggregation propensity and
neurotoxicity in vitro [169, 170]. Taken together, these find-
ings suggest that 𝛼-synuclein ubiquitination and SUMOy-
lation may be coexisting phenomena whose equilibrium
regulates the folding state and the localization of the pro-
tein. In particular, the fact that SUMOylation facilitates the
exosomal-mediated release of 𝛼-synuclein [160] supports the
hypothesis that exosomes might behave as possible “way out”
to eliminate exceeding amount of the protein that cannot be
degraded by conventionalmechanisms such as proteasome or
lysosomedigestion. Further studies are needed to corroborate
the role of exosomes in toxic 𝛼-synuclein spreading and
in the progression of PD. Nonetheless, exosomes and their
cell-to-cell transmission mechanisms could represent novel
intriguing therapeutic targets to lessen or block the evolution
of 𝛼-synuclein pathology.
6. Uptake of Aberrant 𝛼-Synuclein
from Recipient Cells: Consequences on
Synaptic Functions
In the brain, neurons can show differential vulnerabil-
ity to 𝛼-synuclein accumulation. Indeed, even though it
has been reported that in PD subjects LB pathology first
affects the vagal nuclei, locus coeruleus, and olfactory bulbs,
the motor symptoms appear when 𝛼-synuclein deposition
reaches nigrostriatal dopamine neurons. In particular, since
the striatal synaptic accumulation of the protein is much
higher than its deposition in the cell bodies of the sub-
stantia nigra [171], it may be hypothesized that mechanisms
promoting its synaptic translocation could be enhanced in
the early phases of disease. When taking into account the
trans-synaptic spreading hypothesis by Braak, it is feasible
that nigrostriatal dopamine neurons might interpret the
uptake of 𝛼-synuclein pathological seeds as a signal that
prompts them to further promote 𝛼-synuclein trans-synaptic
transfer as a response. In line with this idea, the injection
of synthetic fibrils and LB extracts from PD subjects in the
mouse brain has been found to induce a rapid and progressive
synucleinopathy between anatomically interconnected brain
regions [9, 164, 172–174]. Nonetheless, other studies have
reported considerable difficulties in inducing a widespread
induction of 𝛼-synuclein pathology following intracerebral
administration of amyloidogenic forms of the protein in
mice [175]. Furthermore, several mechanisms, such as neu-
roinflammation, have been found to act synergistically or
independently to promote the spread of pathology following
fibrillary amyloidogenic and nonamyloidogenic 𝛼-synuclein
[175]. This evidence calls into question that extracellular 𝛼-
synuclein can catalyze aggregation and spread of intracellular
protein only through a nucleation dependent conformational
templating mechanism. Worthy of note, besides the fact
that fragmented amyloid-like aggregates of short 𝛼-synuclein
fibrils can function as seeds that trigger prion-like conversion
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[176], the transmission of mature fibrils between cells might
be difficult in light of their dimensions and stability. It is
easier to speculate that they might derive from degenerating
neurons in the parenchyma. On this line, brain propagation
of 𝛼-synuclein has been found to involve nonfibrillar protein
species and to be enhanced in 𝛼-synuclein null mice [177].
In addition, PD-causing 𝛼-synuclein missense mutations
shift native tetramers to monomers as a mechanism for
disease initiation [51]. Extracellular oligomeric species that
are also transmissible through exosomal vesicles [178] are
highly abundant in the PD brain [115] and can promote 𝛼-
synuclein aggregation in recipient cells [179]. Transmitted
electron microscopy studies in the postmortem human brain
of subjects affected by synucleinopathies, reporting the pres-
ence of oligomeric 𝛼-synuclein within the early-endosomal
compartment of neuronal cells, are also in line with the
idea that oligomers might be the transmissible species [13].
However, what could be the cause of their increased accu-
mulation and how they trigger aggregation of endogenous
𝛼-synuclein in recipient cells still needs elucidation. The
release of oligomers might serve to eliminate exceeding
levels of the protein, or it could depend on the activation
of plastic structural adaptive mechanisms in neurons as the
protein is involved in synaptic plasticity [180, 181]. Otherwise,
protein oligomers could behave as a transmissible neuronal
messenger between neighboring neurons. Remarkably, the
higher stability of 𝛼-synuclein oligomers and fibrils renders
these species more suitable to be secreted in the extracellular
space when compared to monomeric protein. Indeed, the
conformation of this latter could bemodulated even by subtle
homeostatic changes in the microenvironment.
Alpha-synuclein uptake could very well contribute to
synaptic damage. Indeed, the protein could accumulate at
synapses by altering the function of endogenous proteins and
engulfing the retrograde transport from the terminals that
receive 𝛼-synuclein to the cell bodies. Alternatively, recipient
cells might collapse as they fail to degrade internalized 𝛼-
synuclein efficiently. It is feasible that the accumulation of
extracellular 𝛼-synuclein in dopaminergic synaptic terminals
can easily initiate synaptic failure given the relevance of the
protein in the regulation of dopamine release [182]. Folding
andmisfolding of endogenous 𝛼-synuclein can bemodulated
by exogenous pathological 𝛼-synuclein forms and then affect,
or be affected by, their interaction with lipid membranes
[183]. Alpha-synuclein binding to lipid membranes can be
either detrimental or protective to neuronal cells [184]. For
instance, A30P, E46K, and A53T disease variants of 𝛼-
synuclein show increased lipid binding affinity [185] although
they have distinct membrane permeabilization properties
[186] and can thus differentially affect membrane structure
[187]. In line with this idea, exogenous 𝛼-synuclein has been
found to induce lipid raft fragmentation thus leading to
both pre- and postsynaptic alterations [114] and 𝛼-synuclein
oligomers can impair long term potentiation (LTP) and
impair synaptic transmission [113].
Finally, a recent study showed that different 𝛼-synuclein
conformers can cross the blood brain barrier and distribute to
the CNS after intravenous injection [89].This novel evidence
suggests that the diffusion of 𝛼-synuclein pathology might
also bemediated bymechanisms other than the simple trans-
synaptic spreading of the protein among interconnected
brain regions.
Looking at the mechanisms of 𝛼-synuclein uptake, while
the soluble monomeric protein can cross the plasma mem-
brane or can be captured by Rab5a-dependent [188] and
dynamin-dependent endocytosis [140], high order assembly
can enter into recipient cells by using different endocytic
pathways [169]. Among the possible mechanisms of uptake,
macropinocytosis has also been explored [189].Other authors
reported that extracellular 𝛼-synuclein uptake by microglial
cells is mediated by the GM1 ganglioside as well as by
hitherto-unknown protein receptors in clathrin-, caveolae-
, and dynamin-independent, but lipid raft-dependent pro-
cesses [90]. However, the caveolae-specific protein caveolin-1
has been found to interact with and to mediate 𝛼-synuclein
toxicity in neuroblastoma cells [190] thus suggesting that the
possibility that the uptake of the protein might be mediated
by caveolae-mediated endocytosis at least in neuronal cells
deserves further investigation. More recently, mesenchymal
stem cells were identified as blockers of the clathrin-mediated
endocytosis of extracellular 𝛼-synuclein, a process that is
controlled by the interaction with NMDA receptor [191].
In addition, the interaction between preformed 𝛼-synuclein
fibrils and immune receptor lymphocyte activation gene 3
(LAG3) has been found to be essential for initiating the
transneuronal propagation of 𝛼-synuclein [192]. This study
clearly opens new avenues for PD therapy as LAG3 antibodies
are already being tested as cancer treatments [193] and
suggested that LAG3 might mediate both immune system
activation and systemic spreading of pathological fibrillary 𝛼-
synuclein species.
The fact that 𝛼-synuclein can be released in association
with exosomes and extracellular vesicles (EV) strongly sug-
gests that these might constitute the primary vehicles of
cell-to-cell transmission of the protein, preserving it from
degradation by extracellular enzymes and facilitating its
correct targeting toward recipient cells. Indeed, given the high
structural instability of the protein and its small size, it is quite
unlikely that 𝛼-synuclein could easily survive in the brain
parenchyma environment in a free and soluble form.
Collectively, these evidences strongly support that 𝛼-
synuclein spreading could very well contribute to synaptic
impairment in PD although the biological factors determin-
ing the selective vulnerability of nigrostriatal neurons, even
on top of the “prion-like” hypothesis, are not yet clear.
7. Concluding Remarks
At present, the spreading hypothesis of 𝛼-synuclein pathol-
ogy is still matter of debate. Indeed, although a plethora
of research studies seem to confirm that 𝛼-synuclein can
diffuse throughout the nervous system, is transmitted from
cell to cell, and could induce toxicity and function as
a seed for the aggregation of endogenous protein, other
evidences seem to confute these findings (Table 1). This,
notwithstanding, data on the transmissibility of the protein
as well as on the misfolding-inducing ability of 𝛼-synuclein
8 Neural Plasticity
Ta
bl
e
1
Fi
rs
ta
ut
ho
r
Ti
tle
Ye
ar
Jo
ur
na
l
Ev
id
en
ce
ss
up
po
rt
in
g𝛼
-sy
nu
cle
in
sp
re
ad
in
g
Br
aa
k
“S
ta
gi
ng
of
Br
ai
n
Pa
th
ol
og
y
Re
lat
ed
to
Sp
or
ad
ic
Pa
rk
in
so
n’s
D
ise
as
e”
20
03
N
eu
ro
bi
ol
.A
gi
ng
D
el
Tr
ed
ic
i
“S
po
ra
di
cP
ar
ki
ns
on
’s
D
ise
as
e:
D
ev
el
op
m
en
ta
nd
D
ist
rib
ut
io
n
of
A
lp
ha
-S
yn
uc
le
in
Pa
th
ol
og
y”
20
16
N
eu
ro
pa
th
ol
.A
pp
l.
N
eu
ro
bi
ol
.
Ilj
in
a
“K
in
et
ic
M
od
el
of
th
eA
gg
re
ga
tio
n
of
A
lp
ha
-S
yn
uc
le
in
Pr
ov
id
es
In
sig
ht
si
nt
o
Pr
io
n-
Li
ke
Sp
re
ad
in
g”
20
16
Pr
oc
.N
at
l.
Ac
ad
.S
ci
.U
SA
O
h
“M
es
en
ch
ym
al
St
em
C
el
ls
In
hi
bi
tT
ra
ns
m
iss
io
n
of
𝛼
-S
yn
uc
le
in
by
M
od
ul
at
in
g
Cl
at
hr
in
-M
ed
ia
te
d
En
do
cy
to
sis
in
aP
ar
ki
ns
on
ia
n
M
od
el
”
20
16
C
el
lR
ep
.
H
elw
ig
“B
ra
in
Pr
op
ag
at
io
n
of
Tr
an
sd
uc
ed
A
lp
ha
-S
yn
uc
le
in
In
vo
lv
es
N
on
-F
ib
ril
la
rP
ro
te
in
Sp
ec
ie
sa
nd
Is
En
ha
nc
ed
in
A
lp
ha
-S
yn
uc
le
in
N
ul
lM
ic
e”
20
16
Br
ai
n
Be
rn
is
“P
rio
n-
Li
ke
Pr
op
ag
at
io
n
of
H
um
an
Br
ai
n-
D
er
iv
ed
A
lp
ha
-S
yn
uc
le
in
in
Tr
an
sg
en
ic
M
ic
eE
xp
re
ss
in
g
H
um
an
W
ild
-T
yp
eA
lp
ha
-S
yn
uc
le
in
”
20
15
Ac
ta
N
eu
ro
pa
th
ol
.C
om
m
un
.
Ill
es
-T
ot
h
“D
ist
in
ct
H
ig
he
r-
O
rd
er
A
lp
ha
-S
yn
uc
le
in
O
lig
om
er
sI
nd
uc
eI
nt
ra
ce
llu
la
rA
gg
re
ga
tio
n”
20
15
Bi
oc
he
m
.J
.
U
lu
so
y
“N
eu
ro
n-
to
-N
eu
ro
n
𝛼
-S
yn
uc
le
in
Pr
op
ag
at
io
n
In
Vi
vo
Is
In
de
pe
nd
en
to
fN
eu
ro
na
lI
nj
ur
y”
20
15
Ac
ta
N
eu
ro
pa
th
ol
.C
om
m
un
.
St
ue
nd
l
“I
nd
uc
tio
n
of
𝛼
-S
yn
uc
le
in
A
gg
re
ga
te
Fo
rm
at
io
n
by
CS
F
Ex
os
om
es
fro
m
Pa
tie
nt
sw
ith
Pa
rk
in
so
n’s
D
ise
as
ea
nd
D
em
en
tia
w
ith
Le
w
y
Bo
di
es
”
20
16
Br
ai
n
Pr
us
in
er
“E
vi
de
nc
ef
or
𝛼
-S
yn
uc
le
in
Pr
io
ns
Ca
us
in
g
M
ul
tip
le
Sy
ste
m
At
ro
ph
y
in
H
um
an
sw
ith
Pa
rk
in
so
ni
sm
”
20
15
Pr
oc
.N
at
l.
Ac
ad
.S
ci
.U
SA
M
as
ud
a-
Su
zu
ka
ke
“P
at
ho
lo
gi
ca
lA
lp
ha
-S
yn
uc
le
in
Pr
op
ag
at
es
th
ro
ug
h
N
eu
ra
lN
et
w
or
ks
”
20
14
Ac
ta
N
eu
ro
pa
th
ol
.C
om
m
un
.
Sa
ci
no
“B
ra
in
In
je
ct
io
n
of
A
lp
ha
-S
yn
uc
le
in
In
du
ce
sM
ul
tip
le
Pr
ot
ei
no
pa
th
ie
s,
G
lio
sis
,a
nd
aN
eu
ro
na
lI
nj
ur
y
M
ar
ke
r”
20
14
J.
N
eu
ro
sc
i.
Ko
va
cs
“I
nt
ra
ce
llu
la
rP
ro
ce
ss
in
g
of
D
ise
as
e-
As
so
ci
at
ed
𝛼
-S
yn
uc
le
in
in
th
eH
um
an
Br
ai
n
Su
gg
es
ts
Pr
io
n-
Li
ke
C
el
l-t
o-
C
el
lS
pr
ea
d”
20
14
N
eu
ro
bi
ol
.D
is.
Re
ca
se
ns
“L
ew
y
Bo
dy
Ex
tr
ac
ts
fro
m
Pa
rk
in
so
n
D
ise
as
eB
ra
in
sT
rig
ge
r𝛼
-S
yn
uc
le
in
Pa
th
ol
og
y
an
d
N
eu
ro
de
ge
ne
ra
tio
n
in
M
ic
ea
nd
M
on
ke
ys
”
20
14
A
nn
.N
eu
ro
l.
U
lu
so
y
“C
au
do
-R
os
tr
al
Br
ai
n
Sp
re
ad
in
g
of
𝛼
-S
yn
uc
le
in
th
ro
ug
h
Va
ga
lC
on
ne
ct
io
ns
”
20
13
EM
BO
M
ol
.M
ed
.
M
as
ud
a-
Su
zu
ka
ke
“P
rio
n-
Li
ke
Sp
re
ad
in
g
of
Pa
th
ol
og
ic
al
𝛼
-S
yn
uc
le
in
in
Br
ai
n”
20
13
Br
ai
n
A
ng
ot
“A
lp
ha
-S
yn
uc
le
in
C
el
l-t
o-
C
el
lT
ra
ns
fe
ra
nd
Se
ed
in
g
in
G
ra
fte
d
D
op
am
in
er
gi
cN
eu
ro
ns
In
Vi
vo
”
20
12
PL
oS
O
ne
Lu
k
“I
nt
ra
ce
re
br
al
In
oc
ul
at
io
n
of
Pa
th
ol
og
ic
al
A
lp
ha
-S
yn
uc
le
in
In
iti
at
es
aR
ap
id
ly
Pr
og
re
ss
iv
eN
eu
ro
de
ge
ne
ra
tiv
e
A
lp
ha
-S
yn
uc
le
in
op
at
hy
in
M
ic
e”
20
12
J.
Ex
p.
M
ed
.
Lu
k
“P
at
ho
lo
gi
ca
lA
lp
ha
-S
yn
uc
le
in
Tr
an
sm
iss
io
n
In
iti
at
es
Pa
rk
in
so
n-
Li
ke
N
eu
ro
de
ge
ne
ra
tio
n
in
N
on
tr
an
sg
en
ic
M
ic
e”
20
12
Sc
ie
nc
e
Ko
rd
ow
er
“T
ra
ns
fe
ro
fH
os
t-D
er
iv
ed
A
lp
ha
Sy
nu
cle
in
to
G
ra
fte
d
D
op
am
in
er
gi
cN
eu
ro
ns
in
Ra
t”
20
11
N
eu
ro
bi
ol
.D
is.
H
an
se
n
“A
lp
ha
-S
yn
uc
le
in
Pr
op
ag
at
es
fro
m
M
ou
se
Br
ai
n
to
G
ra
fte
d
D
op
am
in
er
gi
cN
eu
ro
ns
an
d
Se
ed
sA
gg
re
ga
tio
n
in
Cu
ltu
re
d
H
um
an
C
el
ls”
20
11
J.
Cl
in
.I
nv
es
t.
D
an
ze
r
“S
ee
di
ng
In
du
ce
d
by
A
lp
ha
-S
yn
uc
le
in
O
lig
om
er
sP
ro
vi
de
sE
vi
de
nc
ef
or
Sp
re
ad
in
g
of
A
lp
ha
-S
yn
uc
le
in
Pa
th
ol
og
y”
20
09
J.
N
eu
ro
ch
em
.
Ko
rd
ow
er
“T
ra
ns
pl
an
te
d
D
op
am
in
er
gi
cN
eu
ro
ns
D
ev
elo
p
PD
Pa
th
ol
og
ic
Ch
an
ge
s:
A
Se
co
nd
Ca
se
Re
po
rt
”
20
08
M
ov
.D
iso
rd
.
Ko
rd
ow
er
“L
ew
y
Bo
dy
-L
ik
eP
at
ho
lo
gy
in
Lo
ng
-T
er
m
Em
br
yo
ni
cN
ig
ra
lT
ra
ns
pl
an
ts
in
Pa
rk
in
so
n’s
D
ise
as
e”
20
08
N
at
.M
ed
.
Li
“L
ew
y
Bo
di
es
in
G
ra
fte
d
N
eu
ro
ns
in
Su
bj
ec
ts
w
ith
Pa
rk
in
so
n’s
D
ise
as
eS
ug
ge
st
H
os
t-t
o-
G
ra
ft
D
ise
as
e
Pr
op
ag
at
io
n”
20
08
N
at
.M
ed
.
Ev
id
en
ce
sc
on
fu
tin
g𝛼
-sy
nu
cle
in
sp
re
ad
in
g
Su
m
ik
ur
a
“D
ist
rib
ut
io
n
of
A
lp
ha
-S
yn
uc
le
in
in
th
eS
pi
na
lC
or
d
an
d
D
or
sa
lR
oo
tG
an
gl
ia
in
an
Au
to
ps
y
C
oh
or
to
fE
ld
er
ly
Pe
rs
on
s”
20
15
Ac
ta
N
eu
ro
pa
th
ol
.C
om
m
un
.
Sa
ci
no
“A
m
yl
oi
do
ge
ni
c𝛼
-S
yn
uc
le
in
Se
ed
sD
o
N
ot
In
va
ria
bl
y
In
du
ce
Ra
pi
d,
W
id
es
pr
ea
d
Pa
th
ol
og
y
in
M
ic
e”
20
14
Ac
ta
N
eu
ro
pa
th
ol
.
H
al
lid
ay
“Th
eP
ro
gr
es
sio
n
of
Pa
th
ol
og
y
in
Pa
rk
in
so
n’s
D
ise
as
e”
20
10
A
nn
.N
.Y
.A
ca
d.
Sc
i.
Ja
ng
“N
on
-C
la
ss
ic
al
Ex
oc
yt
os
is
of
A
lp
ha
-S
yn
uc
le
in
Is
Se
ns
iti
ve
to
Fo
ld
in
g
St
at
es
an
d
Pr
om
ot
ed
un
de
rS
tre
ss
C
on
di
tio
ns
”
20
10
J.
N
eu
ro
ch
em
.
H
aw
ke
s
“P
ar
ki
ns
on
’s
D
ise
as
ea
nd
A
gi
ng
:S
am
eo
rD
iff
er
en
tP
ro
ce
ss
?”
20
08
M
ov
.D
iso
rd
.
Ka
la
itz
ak
is
“C
on
tro
ve
rs
ie
so
ve
rt
he
St
ag
in
g
of
A
lp
ha
-S
yn
uc
le
in
Pa
th
ol
og
y
in
Pa
rk
in
so
n’s
D
ise
as
e”
20
08
Ac
ta
N
eu
ro
pa
th
ol
.
Neural Plasticity 9
oligomers and fibrils suggested that these features might
easily perturb synaptic homeostasis, especially in dopamine
neurons. It could be feasible that 𝛼-synuclein release, coupled
to fibrillary insoluble inclusion formation, could deprive
dopamine synaptic terminals from the modulatory action
of the protein. In parallel, the exosome-mediated exchange
of 𝛼-synuclein oligomers between neighboring terminals
could overwhelm intracellular trafficking by encumbering
on the endosomal system. Much work still needs to be
done to define the contribution of 𝛼-synuclein spreading to
PD synaptopathy. However, the determination of what can
be considered as a transmissible pathological form of 𝛼-
synuclein aswell as themechanisms throughwhich this entity
can be transmitted from a diseased presynaptic terminal to a
healthy postsynaptic ending can help us to understand much
more on PD neurobiology and to identify novel effective
therapeutic strategies to cure this disorder. Indeed, whether
PD is primarily a disorder of the synapse, novel effective
therapeutic approaches should both heal diseased synapses
and block the cell-to-cell transmission of toxic 𝛼-synuclein
species.
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